Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.30 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862727 | 0.85 | GABRG2 (0.33) | GRM2IDO1TDO2IDO2MAP4K1 | |
| SCHEMBL833262 | 0.84 | IDO1 (0.34) | IDO1TDO2IDO2DPP4TRPV3 | |
| SCHEMBL832711 | 0.75 | HDAC6 (0.33) | IDO1TDO2IDO2DPP4 | |
| SCHEMBL833246 | 0.72 | PDPK1 (0.46) | — | |
| SCHEMBL10143378 | 0.72 | MAP2K4 (0.34) | DPP4 | |
| SCHEMBL832789 | 0.69 | GABRG2 (0.36) | IDO1TDO2IDO2 | |
| SCHEMBL13394518 | 0.68 | IDO1 (0.33) | IDO1TDO2IDO2TRPV3 | |
| SCHEMBL14920239 | 0.68 | BACE1 (0.41) | — | |
| SCHEMBL481590 | 0.68 | BACE1 (0.41) | — | |
| SCHEMBL10299255 | 0.67 | L3MBTL1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | GRM2 2247/4885IDO1 2/4885TDO2 16/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | GRM2 2287/4885IDO1 1/4885TDO2 12/4885 |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | GRM2 2298/4885IDO1 1/4885TDO2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.